Carregant...
TBOPP enhances the anticancer effect of cisplatin by inhibiting DOCK1 in renal cell carcinoma
The treatment of renal cell carcinoma (RCC) with chemotherapy remains a challenge; therefore, improving the knowledge of the molecular mechanisms underlying RCC chemoresistance and developing novel therapeutic strategies is important. Dedicator of cytokinesis 1 (DOCK1), the first member of the DOCK...
Guardat en:
| Publicat a: | Mol Med Rep |
|---|---|
| Autors principals: | , , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
D.A. Spandidos
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7339706/ https://ncbi.nlm.nih.gov/pubmed/32626999 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mmr.2020.11243 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|